Specificity screening of CAR T cells

Chimeric antigen receptor (CAR) T cell therapy involves engineering the patient’s own immune cells to recognise and attack a specific tumour. It has shown long-term promise in patients with advanced disease. As the therapy works by harnessing the immune system it is crucial that there is no off-target activity that could promote an inappropriate immune response and be very dangerous for the patient.

Retrogenix’s standard approach for specificity screening of CAR T cells initially focused solely on the single chain variable fragment (scFv) that will ultimately be engineered onto the T cells. However, we have now also developed a methodology for labelling and screening the whole CAR T cells themselves. This can provide even greater confidence in the specificity of the therapy. It also provides further support for IND submissions.

 

Screen scFvs or whole CAR T cells

Retrogenix has two approaches for off-target screening of CAR T cells:

  • Screen the antigen recognition element – the scFv
  • Screen whole engineered CAR T cells

Early specificity screening helps select the right scFvs in order to maximise the chances of producing the most promising potential CAR T therapy. This can be followed later by screening of the whole engineered T cell to provide a more physiological assessment of off-target liability.

CAR T cell specificity screen for safety assessment of novel immunotherapies

Download our poster describing the how the Retrogenix human cell microarray technology has been optimised to screen whole CAR T cells for specific interactions, helping reduce the risk of unanticipated off-target adverse effects in the development of novel immunotherapies.

Download poster

FAQ: “How long does a screen take?”

Projects typically take around 8 weeks from when we receive materials through to delivering the results and data package. A single molecule screen using a routine detection system can take as little as 6 weeks. Longer lead times (for example 12 weeks) may be required for some studies including projects where a new detection method is being used as this will need to be optimised with the Retrogenix technology.

See more FAQs

Talk to us about a project
Please leave this field empty.
Pfizer
The University of Sheffield
Aveo Oncology - The Human Response
Theraclone Sciences
BioInvent
AstraZeneca
Bluebird Bio
The Center for Infectious Disease Research
Compugen Logo
The University of Copenhagen
Lund University
MedImmune
NIH - National Institutes of Health
The University of Pennsylvania
Scripps Florida - The Scripps Research Institute
Peptinnovate Ltd - Unlocking Nature's Potential
…working with you was exactly like working with an experienced and knowledgeable scientific collaborator. We had the same types of discussions and strategic planning sessions and I felt confident throughout that we were addressing the issues in the best way possible. It was fun and if I see the opportunity we would do this again.
Professor Mark Kahn, University of Pennsylvania